Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Technology Landscape, Trends and Cancer Biomarker Market. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


The technologies in cancer biomarker has undergone significant change in recent years, with Bence-Jones protein based cancer biomarker to genomic profiling technologies based cancer biomarker. The rising wave of new technologies such as omics and bioinformatics are creating significant potential for advanced cancer biomarker in various medical platforms due to its feature of carefully addressing the heterogeneity issues.

In cancer biomarker market, various technologies such as omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics technologies are used in the diagnostics, research and development, prognostics, and risk assessment applications. Rising incidence of cancer, increasing use of cancer biomarkers in drug discovery and development, and growing research on cancer biomarkers are creating new opportunities for various cancer biomarkers technologies.

Some of the latest technological developments by various countries in the cancer biomarker market are as follows:
  • United States: Illumina, a leading genomics company, announced the launch of a new Omics-based test for early cancer detection. This test has the potential to identify cancers at an earlier stage, when they are more treatable.
  • China: Burning Rock Diagnostics, a Chinese medical device company, received approval from the Chinese government for its lung cancer imaging technology. This technology uses artificial intelligence to analyze lung scans and detect lung cancer nodules. The approval from the Chinese government will allow Burning Rock Diagnostics to commercialize its technology in China, a large and growing market for cancer diagnostics.
  • France: Carbios, a French biotech company, raised $25 million to develop a novel immunoassay-based liquid biopsy test. Liquid biopsies are a minimally invasive way to detect cancer by analyzing cell-free DNA in the blood. Carbios' test has the potential to detect cancer earlier and more accurately than traditional methods.
  • Germany: A team of researchers in Germany published a study in Nature Medicine demonstrating the potential of bioinformatics for personalized cancer treatment. Bioinformatics is the field of science that uses computers to analyze biological data. The study found that bioinformatics can be used to identify genetic mutations that are driving cancer growth. This information can be used to develop targeted therapies that are more effective and have fewer side effects.
This report analyzes technology maturity, degree of disruption, competitive intensity, market potential, and other parameters of various technologies in the cancer biomarker market. Some insights are depicted below by a sample figure. For more details on figures, the companies researched, and other objectives/benefits on this research report, please download the report brochure.


Cancer Biomarker Technology Market

 
Cancer Biomarker Technology Segments
 

 
Cancer Biomarker Technology Heat Map

The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global cancer biomarker technology by application, technology, and region as follows:

Technology Readiness by Technology Type

Competitive Intensity and Regulatory Compliance

Disruption Potential by Technology Type

Trends and Forecasts by Technology [$M shipment analysis from 2018 to 2030]:
  • Omics Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics
  • Bioinformatics
Technology Trends and Forecasts by Application [$M shipment analysis from 2018 to 2030]:
  • Diagnostics
    • Omics Technologies
    • Imaging Technologies
    • Immunoassays
    • Cytogenetics
    • Bioinformatics
  • Research and Development
    • Omics Technologies
    • Imaging Technologies
    • Immunoassays
    • Cytogenetics
    • Bioinformatics
  • Prognostics
    • Omics Technologies
    • Imaging Technologies
    • Immunoassays
    • Cytogenetics
    • Bioinformatics
  • Risk Assessment
    • Omics Technologies
    • Imaging Technologies
    • Immunoassays
    • Cytogenetics
    • Bioinformatics
  • Others
Technology Trends and Forecasts by Region [$M shipment analysis for 2018 to 2030]:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
  • Asia Pacific
    • Japan
    • China
    • South Korea
    • India
  • The Rest of the World

Latest Developments and Innovations in the Cancer Biomarker Technologies

Companies / Ecosystems

Strategic Opportunities by Technology Type

Some of the cancer biomarker companies profiled in this report include Roche, Abbott Laboratories, GlaxoSmithKline, Novartis, Pfizer, and Qiagen.

Below are the latest technological developments from top companies in the cancer biomarker market:
  • F. Hoffmann-La Roche Ltd. (Roche) announced collaboration with Illumina to develop and commercialize next-generation sequencing (NGS) companion diagnostics for cancer immunotherapy.
  • Siemens Healthineers AG received FDA approval for their AI-powered PET imaging system that can improve the detection of small tumors and potentially aid in earlier cancer diagnosis.
  • Abbott Laboratories announced a partnership with Paige AI to integrate Paige's AI algorithms into Abbott's diagnostic imaging platform, aiming to improve the accuracy and efficiency of cancer detection through imaging.
  • Danaher Corporation (Beckman Coulter) launched a new immunoassay test for the detection of a specific cancer biomarker, aiming to provide a more precise and efficient method for cancer diagnosis
  • Agilent Technologies Inc. launched a new cytogenetic microarray specifically designed for cancer diagnostics. This technology allows for a more comprehensive analysis of chromosomal abnormalities associated with cancer.
  • Illumina Inc. announced the development of a new cytogenetic sequencing assay that can identify chromosomal translocations, a critical biomarker for certain cancers.
  • QIAGEN partnered with Microsoft to develop a cloud-based bioinformatics platform for analyzing cancer biomarker data. This collaboration aims to improve the efficiency and accuracy of cancer biomarker research.
This report answers following 9 key questions:
Q.1 What are some of the most promising and high-growth technology opportunities for the cancer biomarker market?
Q.2 Which technology will grow at a faster pace and why?
Q.3 What are the key factors affecting dynamics of different technologies? What are the drivers and challenges of these technologies in cancer biomarker market?
Q.4 What are the levels of technology readiness, competitive intensity and regulatory compliance in this technology space?
Q.5 What are the business risks and threats to these technologies in cancer biomarker market?
Q.6 What are the latest developments in cancer biomarker technologies? Which companies are leading these developments? 
Q.7 Which technologies have potential of disruption in this market?
Q.8 Who are the major players in this cancer biomarker market? What strategic initiatives are being implemented by key players for business growth?
Q.9 What are strategic growth opportunities in this cancer biomarker technology space?
Table of Contents

1. Executive Summary

2. Technology Landscape
2.1. Technology Background and Evolution
2.2. Technology and Application Mapping
2.3. Supply Chain

3. Technology Readiness
3.1. Technology Commercialization and Readiness
3.2. Drivers and Challenges in Cancer Biomarker Technologies
3.3. Competitive Intensity
3.4. Regulatory Compliance

4. Technology Trends and Forecasts Analysis from 2018-2030
4.1. Cancer Biomarker Opportunity
4.2. Technology Trends (2018-2023) and Forecasts (2024-2030)
4.2.1. Omics Technologies
4.2.2. Imaging Technologies
4.2.3. Immunoassays
4.2.4. Cytogenetics
4.2.5. Bioinformatics
4.3. Technology Trends (2018-2023) and Forecasts (2024-2030) by Application Segments
4.3.1. Diagnostics by Technology
4.3.1.1. Omics Technologies
4.3.1.2. Imaging Technologies
4.3.1.3. Immunoassays
4.3.1.4. Cytogenetics
4.3.1.5. Bioinformatics
4.3.2. Research and Development by Technology
4.3.2.1. Omics Technologies
4.3.2.2. Imaging Technologies
4.3.2.3. Immunoassays
4.3.2.4. Cytogenetics
4.3.2.5. Bioinformatics
4.3.3. Prognostics by Technology
4.3.3.1. Omics Technologies
4.3.3.2. Imaging Technologies
4.3.3.3. Immunoassays
4.3.3.4. Cytogenetics
4.3.3.5. Bioinformatics
4.3.4. Risk Assessment by Technology
4.3.4.1. Omics Technologies
4.3.4.2. Imaging Technologies
4.3.4.3. Immunoassays
4.3.4.4. Cytogenetics
4.3.4.5. Bioinformatics
4.3.5. Others by Technology

5. Technology Opportunities (2018-2030) by Region
5.1. Cancer Biomarker Market by Region
5.2. North American Cancer Biomarker Technology Market
5.2.1. United States Cancer Biomarker Technology Market
5.2.2. Canadian Cancer Biomarker Technology Market
5.2.3. Mexican Cancer Biomarker Technology Market
5.3. European Cancer Biomarker Technology Market
5.3.1. The United Kingdom Cancer Biomarker Technology Market
5.3.2. German Automotive Cancer Biomarker Technology Market
5.3.3. French Automotive Cancer Biomarker Technology Market
5.4. APAC  Cancer Biomarker Technology Market
5.4.1. Chinese Cancer Biomarker Technology Market
5.4.2. Japanese Cancer Biomarker Technology Market
5.4.3. Indian Cancer Biomarker Technology Market
5.4.4. South Korean Cancer Biomarker Technology Market
5.5. ROW Cancer Biomarker Technology Market

6. Latest Developments and Innovations in the Cancer Biomarker Technologies

7. Companies / Ecosystem
7.1. Product Portfolio Analysis
7.2. Market Share Analysis
7.3. Geographical Reach

8. Strategic Implications
8.1. Implications
8.2. Growth Opportunity Analysis
8.2.1. Growth Opportunities for the Cancer Biomarker Market by Technology
8.2.2. Growth Opportunities for the Cancer Biomarker Market by Application
8.2.3. Growth Opportunities for the Cancer Biomarker Market by Region
8.3. Emerging Trends in the Cancer Biomarker Market
8.4. Disruption Potential
8.5. Strategic Analysis
8.5.1. New Product Development
8.5.2. Capacity Expansion of the Cancer Biomarker Market
8.5.3. Mergers, Acquisitions, and Joint Ventures in the Cancer Biomarker Market  

9. Company Profiles of Leading Players
9.1. Roche
9.2. Abbott Laboratories
9.3. GlaxoSmithKline
9.4. Novartis
9.5. Pfizer
9.6. Qiagen
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Technology Landscape, Trends and Opportunities in the Global Cancer Biomarker Market Full Report $ 4,850
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Technology Landscape, Trends and Opportunities in the Global Cancer Biomarker Market.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )
Have an Account / Returning Visitors?

Follow us on